Related Experiment Video
Updated: May 8, 2025

06:06
Color Spot Test As a Presumptive Tool for the Rapid Detection of Synthetic Cathinones
Published on: February 5, 2018
24.6K
National Poison Data System® Annual Report: under the hood.
1Indiana Poison Center, Indiana University Health, Lebanon, Indiana, USA.
Clinical Toxicology (Philadelphia, Pa.)
|December 24, 2024
Summary
The National Poison Data System (NPDS) offers unique insights into poisoning epidemiology in the U.S. Its rigorous fatality review process and narrative reporting distinguish it from other surveillance systems.
Area of Science:
- Toxicology
- Public Health Surveillance
- Epidemiology
Background:
- The 41st National Poison Data System (NPDS) Annual Report is published, necessitating a review of U.S. poisoning surveillance.
- Understanding the strengths and weaknesses of NPDS is crucial for accurate public health data interpretation.
Purpose of the Study:
- To compare the National Poison Data System (NPDS) with other U.S. poisoning surveillance systems.
- To highlight the strengths and weaknesses of the NPDS.
- To review the NPDS fatality review process.
Main Methods:
- Comparative analysis of NPDS with ToxIC Registry, WISQARS, and CDC WONDER.
- Detailed review of the NPDS fatality review process for mortality data.
- Examination of differences in scope, focus, data sources, and reporting.
Main Results:
- NPDS, ToxIC, WISQARS, and CDC WONDER differ in population base, reporting sources, statistical sampling, outcomes, and reported products/substances.
- NPDS provides a unique epidemiological perspective, distinct yet complementary to other systems.
- NPDS features a rigorous fatality review process with input verification and unique publication of fatality narratives.
Conclusions:
- NPDS data offers a distinct and complementary view of U.S. poisoning epidemiology.
- The NPDS fatality review process enhances data verification.
- Publication of fatality narratives is a unique and valuable feature of the NPDS.
Related Concept Videos
Anticholinesterase Agents: Poisoning and Treatment
729
Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
729
Prevention of Further Absorption of Poison
738
In cases of acute poisoning, the primary objective is to prevent further absorption of the toxic substance into the body. Immediate interventions using various decontamination techniques targeting the gastrointestinal (GI) tract can achieve this. Decontamination is crucial to prevent poison from entering the systemic circulation, which involves washing affected areas with water and mild soap and removing contaminated clothing. Once external decontamination is done, attention must be turned to...
738
Enhanced Elimination of Poison
454
Poison can be effectively removed from the gastrointestinal (GI) tract through various decontamination procedures.
Antidotes serve a crucial role in counteracting the effects of poison by inhibiting enzymes responsible for producing harmful drug metabolites. In some cases, these toxic metabolites can be neutralized by endogenous cosubstrates, which are maintained at specific concentrations to prevent interaction with cellular macromolecules and subsequent cell death.
Renal excretion is the...
Antidotes serve a crucial role in counteracting the effects of poison by inhibiting enzymes responsible for producing harmful drug metabolites. In some cases, these toxic metabolites can be neutralized by endogenous cosubstrates, which are maintained at specific concentrations to prevent interaction with cellular macromolecules and subsequent cell death.
Renal excretion is the...
454
Antidotes
593
Antidotes are medicinal substances used to counteract the harmful effects of toxins or drugs in the body. They function in various ways, each uniquely designed to combat specific toxic compounds.
Specific antidotes operate by inhibiting the enzymes that control biochemical pathways, reducing the production of harmful metabolites.
An example of an antidote is atropine, which counteracts the detrimental effects of cholinesterase inhibitors. It achieves this by deactivating muscarinic receptors,...
Specific antidotes operate by inhibiting the enzymes that control biochemical pathways, reducing the production of harmful metabolites.
An example of an antidote is atropine, which counteracts the detrimental effects of cholinesterase inhibitors. It achieves this by deactivating muscarinic receptors,...
593
Drug Nomenclature
1.5K
During the development of a new pharmaceutical, the manufacturer initially assigns a code name to the drug. Once approved, the drug receives a United States Adopted Name (USAN)—a generic, nonproprietary designation. Upon being listed in the United States Pharmacopeia, this nonproprietary name becomes the drug's official name. Additionally, the manufacturer assigns a proprietary name or trademark, which serves as the brand name under which the drug is marketed. It is worth noting that...
1.5K
Pharmacovigilance
732
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
732

